LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.68% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Misses Q4 Earnings and Revenue Estimates

BURLINGTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2021 results, announced a $0.125/share quarterly dividend (+14%) and provided guidance.

LeMaitre Q4 2021 Financial Results

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for

BURLINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Fourth Quarter 2021 Earnings Results February 24, 2022

BURLINGTON, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 10:30 AM ET.

LeMaitre to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

AdaptHealth Corp

AHCO vs. LMAT: Which Stock Is the Better Value Option?

AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?

BURLINGTON, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 24th Annual Needham Virtual Growth Conference on Friday, January 14, 2022, at 3:30 PM.

LeMaitre to Present at the Needham Virtual Growth Conference

LeMaitre Vascular is a small-cap medical devices maker with the potential to continue growing rapidly in the years ahead.

Why You Should Consider Buying This Little-Known Medical Devices Stock

BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming virtual investor conferences.

LeMaitre to Participate at Upcoming Investor Conferences

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2021 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.09% and -2.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Lags Q3 Earnings and Revenue Estimates

LeMaitre Vascular (NASDAQ:LMAT) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Recap: LeMaitre Vascular Q3 Earnings

BURLINGTON, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2021 results, announced an $0.11/share quarterly dividend and provided guidance.

LeMaitre Q3 2021 Financial Results

BURLINGTON, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2021 financial results on Thursday, October 28, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Third Quarter 2021 Earnings Results on October 28, 2021

Descartes Systems Group

Alphabet

Old Dominion Freight Line

West Pharmaceutical Services

In light of increasing market volatility, five stocks with high business quality and have outperformed the Standard & Poor's 500 index in the year to date are Alphabet Inc. ( GOOGL , Financial)( GOOG , Financial), Old Dominion Freight Line ( ODFL , Financial), West Pharmaceutical Services Inc. ( WST , Financial), The Descartes Systems Group Inc. ( DSGX , Financial) and LeMaitre Vascular Inc. ( LMAT , Financial) according to the High Quality Low CapEx Screener, a Premium screen nested within GuruFocus' All-in-One Screener.

5 High-Quality Stocks Outperforming the S&P 500

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four virtual investor conferences in September.

LeMaitre Vascular to Participate at Upcoming Investor Conferences in September

LeMaitre Vascular's operating fundamentals and balance sheet suggest it's a buy, depending on your objectives.

Is This Under-the-Radar Medical Device Company a Post-Earnings Buy?

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2021 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 17.65% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Beats Q2 Earnings Estimates

BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2021 results, announced an $0.11/share quarterly dividend and provided guidance.

LeMaitre Q2 2021 Financial Results

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "

BURLINGTON, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2021 financial results on Thursday, July 29, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Second Quarter 2021 Earnings Results on July 29, 2021

LeMaitre Vascular (LMAT) to Report Q2 Results: Wall Street Expects Earnings Growth

LeMaitre Vascular Inc (NASDAQ: LMAT) has announced preliminary Q2 2021 results and sees net sales of $40.7 million compared to an estimated $37.9 million, up 64%Y/Y on a reported basis and +35% organically. It expects gross margin in the range of 65.5% to 66.1%, -2.7% at the midpoint vs.

LeMaitre Vascular Sees Better Than Expected Q2 Sales, Raises $55M Via Equity At 9% Discount

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $54.50 per share. Gross proceeds to LeMaitre from the offering are expected to be approximately $54.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by LeMaitre. The offering is expected to close on or about July 16, 2021, subject to customary closing conditions. LeMaitre has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 150,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

News for LeMaitre Vascular Stock (LMAT)